Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127080681 | 12708068 | 1 | I | 20160718 | 20160824 | 20160901 | 20160901 | EXP | FR-ASTRAZENECA-2016SE92214 | ASTRAZENECA | 4332.00 | DY | M | Y | 48.00000 | KG | 20160901 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127080681 | 12708068 | 1 | PS | INEXIUM | ESOMEPRAZOLE | 1 | Oral | 300 | MG | Y | U | 21153 | 20 | MG | QD | ||||
| 127080681 | 12708068 | 2 | SS | KIDROLASE | ASPARAGINASE | 1 | Intravenous bolus | 15000.0IU EVERY CYCLE | Y | U | 0 | ||||||||
| 127080681 | 12708068 | 3 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous bolus | 2.0MG EVERY CYCLE | Y | U | 0 | 2 | MG | ||||||
| 127080681 | 12708068 | 4 | SS | CERUBIDINE | DAUNORUBICIN HYDROCHLORIDE | 1 | Intravenous bolus | 44.0MG EVERY CYCLE | Y | U | 0 | 44 | MG | ||||||
| 127080681 | 12708068 | 5 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 0.4286 DF, THREE TIMES A WEEK | Y | U | 0 | ||||||||
| 127080681 | 12708068 | 6 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Intravenous bolus | 1305 | MG | Y | U | 0 | 87 | MG | QD | ||||
| 127080681 | 12708068 | 7 | C | DOLIPRANE | ACETAMINOPHEN | 1 | 0 | ||||||||||||
| 127080681 | 12708068 | 8 | C | SPASFON | PHLOROGLUCINOL | 1 | 0 | ||||||||||||
| 127080681 | 12708068 | 9 | C | D VITAMIN | 2 | 0 | |||||||||||||
| 127080681 | 12708068 | 10 | C | CALCIUM | CALCIUM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127080681 | 12708068 | 1 | Gastritis prophylaxis |
| 127080681 | 12708068 | 2 | Lymphoma |
| 127080681 | 12708068 | 3 | Lymphoma |
| 127080681 | 12708068 | 4 | Lymphoma |
| 127080681 | 12708068 | 5 | Infection prophylaxis |
| 127080681 | 12708068 | 6 | Lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127080681 | 12708068 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127080681 | 12708068 | Gamma-glutamyltransferase increased | |
| 127080681 | 12708068 | Hepatic steatosis | |
| 127080681 | 12708068 | Hepatocellular injury | |
| 127080681 | 12708068 | Hepatomegaly | |
| 127080681 | 12708068 | Jaundice | |
| 127080681 | 12708068 | Splenomegaly |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127080681 | 12708068 | 1 | 20160704 | 20160805 | 0 | |
| 127080681 | 12708068 | 2 | 20160715 | 20160802 | 0 | |
| 127080681 | 12708068 | 3 | 20160711 | 20160801 | 0 | |
| 127080681 | 12708068 | 4 | 20160711 | 20160801 | 0 | |
| 127080681 | 12708068 | 5 | 20160704 | 20160803 | 0 | |
| 127080681 | 12708068 | 6 | 20160704 | 20160804 | 0 |